The
by
DelveInsight analyses that the market will experience a boost due to the increase in the patient pool and launch of the emerging therapies such as
Abilify, Lumateperone/ITI-007, NRX-100/NRX-101, Zuranolone, SEP-4199, and Falkieri during the forecast period.
The
report offers insights on disease comprehension, historical and forecasted epidemiology; and Bipolar Depression market trends in the 7MM (United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan). The research report also covers the current Bipolar Depression treatment practice/algorithm, market drivers, market barriers and unmet medical needs to evaluate the underlying potential of the Bipolar Depression market.
ResearchAndMarkets.com’s offering.
This ‘Adrenoleukodystrophy (ALD) – Epidemiology Forecast to 2030’ report delivers an in-depth understanding of the disease, historical and forecasted Adrenoleukodystrophy epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.
Adrenoleukodystrophy (ALD) Understanding
Adrenoleukodystrophy (ALD) is an X-linked recessive genetic disorder caused by the abnormality in the ABCD1 gene present on the X chromosome that leads to the accumulation of very-long-chain fatty acids (VLCFAs) in the brain, nervous system, and adrenal gland.
The accumulation of VLCFAs leads to the deterioration of the myelin sheath, and without the sheath, neurons cannot conduct action potentials, this leads to the development of seizures and hyperactivity. There are three basic forms of ALD: neonatal, childhood, and adult-onset. The childhood ALD is the classical and the most severe form leading to total d
Global Adrenoleukodystrophy (ALD) Epidemiology Forecast to 2030 - ResearchAndMarkets com - Press Release digitaljournal.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from digitaljournal.com Daily Mail and Mail on Sunday newspapers.